In particular, Programmed Cell Death 1 (PD-1) seems to play a critical role in preventing tumor rejection and PD-1 blocking antibodies have shown impressive activity in melanoma, NSCLC, and bladder cancer, among others. The gene discussed is PDCD1; the disease is melanoma.